: Remicade. ?  »
|
-

I.V

Powder For Concentrate For Infusion

- Adult :- Crohn`s disease: Treatment of moderate to severe active Crohn`s disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn`s disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - Paediatric Crohn`s disease: Remicade is indicated for: Treatment of severe active crohn`s disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy - Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - Psoriatic arthritis : Remicade is indicated for : Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - Remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. - Rheumatoid arthritis: Remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: Patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. Patients with severe active and progressive disease not previously treated with methotrexate or other DMARDs. In this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - Psoriasis: Remicade is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or PUVA. - Ulcerative colitis: Remicade is indicated for: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-MP or AZA or who are intolerant to or have medical contraindications for such therapies.- Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 MP or AZA, or who are intolerant to or have medical contraindications for such therapies

137 18 29865 05

Janssen Biologics B.v, The Netherland

12/2014 - 12/2024

.
, .
.
/
Infliximab 100.0 MG/VIAL
Vial 20 ml glass type i 1 x VIAL 36

*

*

 

.

 
" !
 

?
!
 »
183
,